Anxiety, Depression, and Caregiver Burden Among Family Caregivers of Cancer Survivors. [PDF]
Qadire MA +4 more
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Adaptation and resilience in families of cancer survivors: a scoping review protocol on their dual impact on caregiver burden and post-traumatic growth. [PDF]
Peng P +9 more
europepmc +1 more source
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
Caregiver burden in advanced cancer in tertiary care palliative medicine. [PDF]
Quadir SS +5 more
europepmc +1 more source
Caregiver burden in children with medical complexity: an approach based on the identification of associated factors. [PDF]
Albuquerque FSDME +3 more
europepmc +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
Caregiver burden in informal caregivers of cardiac patients: a mixed-methods systematic review. [PDF]
Beheshtaeen F +5 more
europepmc +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source

